Quick Answer
Ernexa Therapeutics Inc. reported Stockholders Equity of $2.40 million for fiscal year 2025.
Ernexa Therapeutics Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $2.40M | +41.2% |
| 2024 | $1.70M | -23.8% |
| 2023 | $2.23M | -81.6% |
| 2022 | $12.11M | -52.5% |
| 2021 | $25.50M | +233.0% |
| 2020 | $7.66M | -21.4% |
| 2019 | $9.74M | +40.9% |
| 2018 | $6.92M | +24.9% |
| 2017 | $5.54M | +36.1% |
| 2016 | $4.07M | +5.7% |
| 2015 | $3.85M | -64.8% |
| 2014 | $10.92M | +18.7% |
| 2013 | $9.20M | +16.6% |
| 2012 | $7.89M | +24.3% |
| 2011 | $6.35M | -32.9% |
| 2010 | $9.46M | +0.5% |
| 2009 | $9.42M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $3.57M | +107.9% | -19.6% |
| June 30, 2025 | $4.44M | +152.1% | +174.7% |
| March 31, 2025 | -$5.95M | -74.4% | -449.8% |
| December 31, 2024 | $1.70M | -23.8% | +103.7% |
| September 30, 2024 | -$45.39M | -1374.4% | -432.4% |
| June 30, 2024 | -$8.53M | -320.5% | -149.9% |
| March 31, 2024 | -$3.41M | -146.2% | -252.8% |
| December 31, 2023 | $2.23M | -81.6% | -37.3% |
- Ernexa Therapeutics Inc. showed an increase of +41.2% in Stockholders Equity compared to the prior fiscal year.
- Over the 2009–2025 period, Ernexa Therapeutics Inc.’s stockholders equity has declined by 74.5% (from $9.42 million to $2.40 million).
- The most recent figure is from Ernexa Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 13, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: